PALI logo

PALI
Palisade Bio Inc

19,577
Mkt Cap
$348.24M
Volume
4.69M
52W High
$2.86
52W Low
$0.53
PE Ratio
-1.40
PALI Fundamentals
Price
$2.08
Prev Close
$2.17
Open
$2.18
50D MA
$1.93
Beta
1.02
Avg. Volume
3.97M
EPS (Annual)
-$0.3014
P/B
2.56
Rev/Employee
$0.00
$2.49
Loading...
Loading...
News
all
press releases
These Stocks Could Rip into the Close
As the market barrels into the final hour of trading, momentum is clustering around a powerful trio of themes, AI infrastructure, next-gen materials, and sustainable agriculture. $KBLB, $LOCL, $MRVL, $POET, $PALI, $FFAI
24-7 Market News·5d ago
News Placeholder
More News
News Placeholder
Analysts Offer Predictions for Palisade Bio Q1 Earnings
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Palisade Bio in a research note issued to...
MarketBeat·5d ago
News Placeholder
Brokers Issue Forecasts for Palisade Bio Q3 Earnings
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Stock analysts at Brookline Capital Markets issued their Q3 2026 EPS estimates for Palisade Bio in a research report issued on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.06) per share for th...
MarketBeat·6d ago
News Placeholder
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports...
MarketBeat·15d ago
News Placeholder
Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy
Wolfe Research upgraded shares of Palisade Bio to a "strong-buy" rating in a report on Wednesday...
MarketBeat·16d ago
News Placeholder
Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI)
Wolfe Research assumed coverage on shares of Palisade Bio in a report on Thursday. They set an "outperform" rating and a $7.00 price objective for the company...
MarketBeat·17d ago
News Placeholder
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn's Efficacy Signals
Palisade Bio (NASDAQ:PALI) said it generated encouraging safety, pharmacokinetic and early efficacy signals from an open-label Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease, a difficult-to-treat population where patients often progress from inflammation to structural fibrosis and may...
MarketBeat·26d ago
News Placeholder
HC Wainwright Forecasts Palisade Bio Q1 Earnings
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Palisade Bio in a research report issued on...
MarketBeat·27d ago
News Placeholder
HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI)
HC Wainwright started coverage on Palisade Bio in a research report on Thursday. They issued a "buy" rating and a $7.00 price objective for the company...
MarketBeat·1mo ago
News Placeholder
Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS
Palisade Bio (NASDAQ:PALI - Get Free Report) released its quarterly earnings results on Friday. The company reported $1.08 EPS for the quarter, beating the consensus estimate of ($0.02) by $1.10...
MarketBeat·1mo ago
<
1
2
...
>

Latest PALI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.